Template:STEMI: Difference between revisions
No edit summary |
No edit summary |
||
| Line 29: | Line 29: | ||
[[ST Elevation Myocardial Infarction Coronary Artery Bypass Grafting|CABG]] • [[ST Elevation Myocardial Infarction Management of Patients Who Were Not Reperfused|Management of Patients Who Were Not Reperfused]] • [[ST Elevation Myocardial Infarction Assessing Success of Reperfusion|Assessing Success of Reperfusion]] | [[ST Elevation Myocardial Infarction Coronary Artery Bypass Grafting|CABG]] • [[ST Elevation Myocardial Infarction Management of Patients Who Were Not Reperfused|Management of Patients Who Were Not Reperfused]] • [[ST Elevation Myocardial Infarction Assessing Success of Reperfusion|Assessing Success of Reperfusion]] | ||
'''Antithrombin Therapy''' • [[ST | '''Antithrombin Therapy''' • [[ST elevation myocardial infarction antithrombin therapy|Antithrombin therapy]] • [[ST elevation myocardial infarction antithrombin therapy#Unfractionated Heparin|Unfractionated heparin]] • [[[[ST elevation myocardial infarction antithrombin therapy#LOW-MOLECULAR-WEIGHT HEPARIN| Low Molecular Weight Heparinoid Therapy]] • [[ST elevation myocardial infarction antithrombin therapy#Direct Thrombin Inhibitors (DTIs) | Direct Thrombin Inhibitor Therapy]] • [[ ST elevation myocardial infarction antithrombin therapy# Factor Xa Inhibition|Factor Xa Inhibition]] | ||
'''Antiplatelet Agents''' • [[ST Elevation Myocardial Infarction Aspirin Therapy|Aspirin]] • [[ST Elevation Myocardial Infarction Thienopyridine Therapy|Thienopyridine Therapy]] • [[ST Elevation Myocardial Infarction Glycoprotein IIbIIIa Inhibition|Glycoprotein IIbIIIa Inhibition]] | '''Antiplatelet Agents''' • [[ST Elevation Myocardial Infarction Aspirin Therapy|Aspirin]] • [[ST Elevation Myocardial Infarction Thienopyridine Therapy|Thienopyridine Therapy]] • [[ST Elevation Myocardial Infarction Glycoprotein IIbIIIa Inhibition|Glycoprotein IIbIIIa Inhibition]] | ||
Revision as of 02:20, 16 February 2009
{{Navbox | name = STEMI | title = ST Elevation Myocardial Infarction | titlestyle = background:Pink; | groupstyle = background:MistyRose; | group1 = Background | list1 = Overview • Epidemiology and Demographics • Classification
| group2 = Risk factors and Triggers | list2 = Risk Factors • Triggers
| group3 = Pathophysiology | list3 = Pathophysiology of Vessel Occlusion • Pathophysiology of Reperfusion• Gross Pathology • Histopathology
| group4 = Diagnosis | list4 = Diagnosis • Symptoms • Differential Diagnosis of Chest Pain • Physical Examination • Electrocardiogram • Right ventricular myocardial infarction • Atrial Infarction • Cardiac Markers • Coronary Angiography
| group5 = Treatment | list5 = Pre-Hospital Care Pre-Hospital Care Initial Care Initial Care • Oxygen • Nitrates • Analgesics • Aspirin • Beta Blockers
Pharmacologic Reperfusion • Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI) • Fibrinolysis
Mechanical Reperfusion • The Importance of Reducing Door-to-Balloon Times • Primary PCI • Adjunctive and Rescue PCI • Rescue PCI • Facilitated PCI • Adjunctive PCI • CABG • Management of Patients Who Were Not Reperfused • Assessing Success of Reperfusion
Antithrombin Therapy • Antithrombin therapy • Unfractionated heparin • [[ Low Molecular Weight Heparinoid Therapy • Direct Thrombin Inhibitor Therapy • Factor Xa Inhibition Antiplatelet Agents • Aspirin • Thienopyridine Therapy • Glycoprotein IIbIIIa Inhibition
Inhibition of the Renin-Angiotensin-Aldosterone System • Inhibition of the Renin-Angiotensin-Aldosterone System
Other Adjunctive Therapies • Magnesium Therapy • Glucose Control • Calcium Channel Blocker Therapy
| group6 = Monitoring | list6 = Arrhythmia Monitoring
| group7 = Complications | list7 = Complications
| group8 = Discharge Care | list8 =Secondary Prevention • Cardiac Rehabilitation • Prognosis }}